Monte Rosa Therapeutics Inc

NASDAQ:GLUE   11:18:12 AM EDT
17.15
-0.34 (-1.97%)
Earnings Announcements

Monte Rosa Therapeutics Announces First Development Candidate And Reports Q3 2021 Financial Results

Published: 11/10/2021 12:50 GMT
Monte Rosa Therapeutics Inc (GLUE) - Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates.
Monte Rosa Therapeutics Inc - Expects Its Cash and Cash Equivalents, Including Aggregate Net Proceeds From Ipo, Will Be Sufficient to Fund Planned Operations and Capital Expenditures Into Late 2024.
Monte Rosa Therapeutics Inc - Qtrly Loss per Share $0.43.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.48

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.48

More details on our Analysts Page.